SNU-398Homo sapiens (Human)Cancer cell line
Also known as: NCI-SNU-398, SNU398
Quick Overview
Human hepatocellular carcinoma cell line with TERT promoter mutations and genomic instability.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0077 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Liver[UBERON:UBERON_0002107] |
Donor Information
| Age | 42 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | asian |
Disease Information
| Disease | Adult hepatocellular carcinoma |
|---|---|
| Lineage | Liver |
| Subtype | Hepatocellular Carcinoma |
| OncoTree Code | HCC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000221_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Ser215Ile (c.644G>T) | Heterozygous | - | from parent cell line SNU-398 |
| MutationSimple | CTNNB1 | p.Ser37Cys (c.110C>G) | Heterozygous | - | from parent cell line SNU-398 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
A pharmacogenomic landscape in human liver cancers.";
Hui L.-J.
Cancer Cell 36:179-193.e11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Gastroenterology 157:760-776(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D., Yildiz G., Ozturk M.
World J. Gastroenterol. 21:311-317(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
Nat. Commun. 4:2218.1-2218.7(2013).
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Xu J.-C.
Hepatology 58:706-717(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.
Won Y.-J., Kim S.-T., Park J.-G.
Int. J. Cancer 67:898-902(1996).